Two further substantial contracts for Proteome Sciences
Proteome Sciences (AIM:PRM), is pleased to announce that following the Company’s announcement dated 8 December 2025, the Company has secured two further substantial Good Clinical Laboratory Practice (“GCLP”) contracts. The contracts have a combined value in excess of $1.5m. Trial samples are expected to be shipped in late Q1 this year, with the major part of the contracts completed in 2026.
Substantial contract for Proteome Sciences
Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a third contract from a US biopharmaceutical company using the Company’s mass spectrometry services to develop a new assay at the company’s facilities in Frankfurt, Germany in anticipation of starting a new clinical trial programme next year.
Appointment of Nominated Adviser and Broker
Proteome Sciences (AIM:PRM), is pleased to announce that SP Angel Corporate Finance LLP has been appointed as the Company’s new Nominated Adviser and sole Broker with immediate effect
Interim results for the six months ended 30 June 2025
Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2025
Result of Annual General Meeting (AGM)
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 noon today, all resolutions were duly passed.
Investor Presentation - Final Results 2024
Final results for the year ended 31 December 2024
The Company is pleased to announce its audited results for the year ended 31 December 2024.
Notice of Results and Investor Presentation
Proteome Sciences (AIM: PRM) announces that the Company’s results for the year ending 31 December 2024 will be announced on 10 April 2025 (the “Final Results”). The Company looks forward to updating shareholders on the Company’s performance and on the outlook for 2025.
On the 11 April 2025 at 10:30 BST the Company’s Executive Chairman, Christopher Pearce and Dr Ian Pike, the Chief Scientific Officer (CSO), will provide a live presentation relating to the Final Results via Investor Meet Company.
Substantial contract for Proteome Sciences
Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a contract win from a US biopharmaceutical company using the Company’s mass spectrometry services for the analysis of samples for an on-going clinical trial. This project will be provided utilising the Good Clinical Laboratory Practice (“GCLP”) accreditation obtained by Proteome Sciences specifically for this type of project.